Skyepharma selects Veratrak platform to ensure secure data storing and sharing
Using Veratrak's platform, the CDMO will have full oversight of data, including an audit trail of data and document processes
French contract development and manufacturing organisation (CDMO) Skyepharma has selected UK-based software provider Veratrak to guarantee data integrity for batch manufacturing records.
Veratrak's platform, which is purpose-built for the life science industry, will ensure data integrity and enable secure data sharing throughout the CDMO's supply chain by leveraging blockchain to store data as part of an immutable ledger, providing an auditable, compliant solution for critical document transfer and safeguarding data security.
Using the platform, contract service organisations and life science companies can securely store and share data across partners in the supply chain, gaining visibility to collaborative processes with their partners.
The cloud-based software as a solution (SaaS) product can be integrated into existing internal systems, such as enterprise ERP software, which means implementation is simple and fast.
Veratrak’s reporting capabilities will give Skyepharma insight into KPIs such as lead time and right-first-time percentage to capture quality and efficiency gains.
Aline Moulin, Pharmaceutical Development Director at Skyepharma, said Veratrak's platform will enable it to "streamline the onboarding of new customers and securely exchange manufacturing, quality and analytical data with them".
Related News
-
News Pharmaceutical Supply Chain People Moves
The latest appointments, promotions, and structural changes across the pharmaceutical supply chain.
-
News Merck KGaA to buy US biotech SpringWorks for US$3.9 billion
The German multinational pharmaceutical company Merck KGaA have signed a deal to buy US biotech company SpringWorks Therapeutics at an equity value of US$3.9 billion in a move to add rare cancer therapeutics to their pipelines.
-
News Cassava Sciences halts Alzheimer's drug trial after limited progress
Cassava Sciences have drawn a close to their investigations and development of the drug simufilam, which they intended to be used for the treatment of Alzheimer’s disease.
-
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines.
-
News Vertex Pharmaceuticals stock jumps as FDA approves non-opioid painkiller
UK-based Vertex Pharmaceuticals saw their stock shares soar as the US FDA signed off on the non-opioid painkiller Journavx, also known as suzetrigine, for patients with moderate to severe acute pain, caused by surgery, accidents, or injuries.
-
News Lessons from CPHI Milan 2024: Sunny Intervals for Pharma Manufacturing?
As the 2024 CPHI conference wrapped up in Milan, we caught up with L.E.K. Consulting – a global strategy consulting firm with deep expertise in pharma manufacturing – to discuss evolving market perspectives and business outlook. -
News US BIOSECURE Act passed by US House of Representatives
The controversial act, which has already impacted several foreign companies operating in the US, was passed by the House of Representatives on September 9, 2024. It is now headed for the US Senate before it can be signed into law by President Joe Biden... -
News Drug prices agreed upon as part of the US Inflation Reduction Act
The Inflation Reduction Act brought into constitution by the Biden administation in 2022, which proposed a drug price negotiation between the government and pharmaceutical companies, has reached it's first agreement.